MMMelissa Maguire

Melissa Maguire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa Maguire has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Helen Gertrude Leyton (1874–1959)

    by Melissa Maguire, Andrew J. Larner


  • Open Access

    Women and the Neurological Society, 1897–1907

    by Melissa Maguire, Andrew J. Larner

    The Neurological Society of London, later the Neurological Society of the United Kingdom, was the first society dedicated to the discipline of neurology to be founded in the United Kingdom. During its period of existence, 1885/1886 to 1907, membership was exclusively male. However, examination of the Society's extant records shows that four women scientists and doctors had interactions with the society: Laura Forster, Rachel Alcock, Mary Darby Sturge, and Helen Stewart. These interactions, examined here, show evidence of the obstructions professional women faced when attempting to enter the male enclave of medical societies, despite the notional inclusivity of the Society's rules and enlightened attitudes evinced by some Society members.


  • Laura Forster (1858–1917)

    by Melissa Maguire, Andrew J. Larner


  • Open Access

    Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability

    by Jon Allard, William Henley, Adrian Sellers, Emma O’sHaughnessy, Oliver Thomson, Brendan McLean, Mary Parrett, Sanjeev Rajakulendran, Lance Watkins, Melissa Maguire, et al.


  • Open Access

    Motor seizures confer overall survival benefit in who grade 2 glioma

    by Sam Fairclough, Paul Chumas, John Goodden, Melissa Maguire, Ryan K. Mathew

    Objective: The prevalence of epilepsy in World Health Organization (WHO) grade 2 glioma is high, with seizures being the presenting symptom in 60%–90%. We explore the epidemiology of seizures in this patient population in a regional neurosurgical center. Methods: Electronic health records of patients with histologically‐proven WHO grade 2 glioma ( n = 228) were reviewed between 1997 and 2021, with data collected including patient demographics, epilepsy prevalence, and seizure semiology. The influence of seizure type on overall survival was calculated using a Cox proportional hazards model. Results: Overall, 197 of 228 patients (86.4%) were diagnosed with epilepsy—either at presentation or during the course of their disease. Male patients were more likely than female patients to be diagnosed with epilepsy (91.1% vs 77.1%, p = .003) and, in those with epilepsy, more likely to experience at least one focal to bilateral tonic–clonic seizure (69.4% vs 54.1%, p = .05). Patients with left‐sided tumors were twice as likely to have experienced a focal to bilateral tonic–clonic seizure ( p = .02, odds ratio [OR] = .47). Predominantly experiencing seizures with motor activity appeared to confer better overall survival, with a 65% decrease in the risk of death 10 years post diagnosis (hazard ratio [HR] = .35, p = .02). This is despite accounting for previously described prognostic markers including tumor histology/genetics, time from diagnosis to surgery, and the extent of tumor resection. Significance: Motor seizure activity is a frequent feature in WHO grade 2 glioma and appears to confer a survival benefit regardless of histology or surgical factors. Seizures due to dominant hemisphere tumors may be more likely to propagate and cause bilateral tonic–clonic activity.


  • Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis

    by Matthew Tanti, University of Leeds, Sarah Nevitt, Molly Yeo, William Bolton, Paul Chumas, Ryan Mathew, Melissa Maguire

    INPLASY202370101 Oedema as a prognostic factor for seizures in meningioma – a systematic review and meta-analysis Keywords: meningioma; seizures; epilepsy; oedema; edema; prognostic factors; …


  • Adult-onset leukoencephalopathy with calcifications and cysts

    by Linford Fernandes, Melissa Maguire, Mark S Igra, Ioannis Mavroudis, Jeremy Cosgrove

  • Open Access

    Levetiracetam as a first‐line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure

    by Sam Fairclough, John Goodden, Paul Chumas, Ryan Mathew, Melissa Maguire

    Objective: The high seizure burden seen in World Health Association (WHO) grade 2 gliomas is well documented. This study aims to identify factors that influence the probability of seizure freedom (12 months of seizure remission) and treatment failure (antiseizure medication [ASM] cessation or introduction of an alternative) in patients with WHO grade 2 glioma.Methods: This is a retrospective observational analysis of patients from a regional UK neurosurgical center with histologically proven (n = 146) WHO grade 2 glioma and brain tumor related epilepsy. Statistical analyses using both Kaplan‐Meier and Cox proportional hazards models were undertaken, with a particular focus on treatment outcomes when the commonly prescribed ASM levetiracetam (n = 101) is used as first line.Results: Treatment with levetiracetam as a first‐line ASM resulted in a significant increase in the probability of seizure freedom (p < .05) at 2 years compared with treatment with an alternative ASM. Individuals presenting with focal seizures without bilateral tonic‐clonic progression were between 39% and 42% significantly less likely to reach seizure freedom within 10 years (p < .05) and 132% more likely to fail treatment by 5 years (p < .01) when compared to individuals who had seizures with progression to bilateral tonic‐clonic activity. ASM choice did not significantly affect treatment failure rates.Significance: More than two‐thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first‐choice agent. Experiencing mainly focal seizures without progression infers a significant long‐term reduction in the chance of seizure freedom. Further studies are needed to inform ASM selection.


  • Open Access

    Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET)

    by James W. Mitchell, Adam Noble, Gus Baker, Rachel Batchelor, Francesco Brigo, Jakob Christensen, Jacqueline French, Antonio Gil-Nagel, Alla Guekht, Nathalie Jette, et al.

    Background: A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as a minimum in all clinical trials. In epilepsy, the choice of outcomes varies widely among existing studies, particularly in clinical trials. This diminishes opportunities for informed decision-making, contributes to research waste and is a barrier to integrating findings in systematic reviews and meta-analyses. Furthermore, the outcomes currently being measured may not reflect what is important to people with epilepsy. Therefore, we aim to develop a COS specific to clinical effectiveness research for adults with epilepsy using Delphi consensus methodology. Methods: The EPSET Study will comprise of three phases and follow the core methodological principles as outlined by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Phase 1 will include two focused literature reviews to identify candidate outcomes from the qualitative literature and current outcome measurement practice in phase III and phase IV clinical trials. Phase 2 aims to achieve international consensus to define which outcomes should be measured as a minimum in future trials, using a Delphi process including an online consensus meeting involving key stakeholders. Phase 3 will involve dissemination of the ratified COS to facilitate uptake in future trials and the planning of further research to identify the most appropriate measurement instruments to use to capture the COS in research practice. Discussion: Harmonising outcome measurement across future clinical trials should ensure that the outcomes measured are relevant to patients and health services, and allow for more meaningful results to be obtained. Core Outcome Set registration: COMET Initiative as study 118.